MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
2. Industry_Business Architects & Consolidators
Industry: By Region (Globally)
Industry: U.S.(United States)
*Industry: Texas
*Industry: Houston
Agennix
Attachments
Agennix
Parents
*Architects: Cancer & Oncology Companies _Pharmaceuticals & Biotechnology
*Architects: Diabetes, Metabolic Disease, Dialysis, Renal & Kidney Companies (Pharmaceuticals, Biotechnology, Biosimilars)
*Industry: Germany
*Industry: Houston
*Industry: New Jersey
Children
*Portfolio Companies: BCM
Agennix AG Raises Approximately € 76 Million in Net Proceeds (2010)
Agennix Awarded Approximately $490,000 Under U.S. Qualifying Therapeutic Discovery Project Grant Program (2010)
Heidelberg, Germany
Houston, Texas
Leader in the development of Talactoferrin Alfa, an immuno-stimulatory protein for pharmaceutical use.
Princeton, New Jersey
Talactoferrin has demonstrated efficacy in Phase 2 placebo-controlled trials in non-small cell lung cancer and diabetic foot ulcers.